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Abstract
Background: Idiopathic portal hypertension (IPH) is a disorder of unknown etiology and is characterized clinically
by portal hypertension, splenomegaly, and hypersplenism accompanied by pancytopenia. This study evaluates the
pathogenic concept of the disease by a systematic review of the literature and illustrates novel pathologic and
laboratory findings.
Case Presentation: We report the first case of uncontrolled splenic hyperperfusion and enlargement with
subsequent hypersplenism leading to life-threatening complications of IPH in infancy and emergent splenectomy.
Conclusions: Our results suggest that splenic NO and VCAM-1, rather than ET-1, have a significant impact on the
development of IPH, even at a very early stage of disease. The success of surgical interventions targeting the
splenic hyperperfusion suggests that the primary defect in the regulation of splenic blood flow seems to be crucial
for the development of IPH. Thus, beside other treatment options splenectomy needs to be considered as a prime
therapeutic option for IPH.
Background
Non-cirrhotic portal hypertension (NCPH) comprises a
group of diseases with increased portal pressure in the
absence of cirrhosis, most of which have portal hyper-
tension as a late manifestation of the disease. Common
causes of NCPH include extrahepatic portal venous
obstruction, non-cirrhotic portal fibrosis or idiopathic
portal hypertension (IPH) [1]. IPH is a rare disorder,
characterized clinically by portal hypertension, spleno-
megaly, and hypersplenism accompanied by pancytope-
nia. Intrahepatic or prehepatic lesions are generally
vascular, either in the portal vein, its branches or in the
perisinusoidal area (‘obliterative portovenopathy’)a n d
cause an increase in portal pressure.
The underlying etiology and pathogenesis are poorly
understood. It has been proposed that infectious, toxic
(exposure to trace metals or chemicals), immunological
a n di m m u n o g e n e t i cf a c t o r sm a yp l a yar o l e[ 1 ] .
As hepatosplenomegaly is the leading symptom, other
causes of organomegaly such as infections, malignancy,
malformations and metabolic disorders, must be ruled
out. In particular, childhood onset points to inherited
conditions involved in early hepatic fibrosis, with special
emphasis on storage disorders. On the other hand, IPH is
not associated with hepatic cirrhosis but portal vein
thrombosis, non-thrombotic causes, and parenchymal
atrophy of the liver secondary to portal malperfusion
[1,2]. Although the etiology remains obscure, either pre-
sinusoidal or extrahepatic vasculopathy lead to elevated
intrahepatic portal resistance [3-5]. The overall prognosis
is generally benign, although catastrophic cases related to
bleeding from esophageal varices may occur [4,6,7].
Till this time, no cases have been described in children
under the age of 10 years. Here we report of a boy who
developed mild hepatomegaly and severe splenomegaly at
8 months of age. Following emergency splenectomy the
child improved rapidly, and all symptoms of the previous
illness disappeared including signs of portal hypertension.
This is the first case of catastrophic IPH in early child-
hood, and to our knowledge the first report of disease
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any medium, provided the original work is properly cited.remission in childhood by surgical means. This points to
the spleen as the origin for disease progression in IPH
patients. We present a detailed diagnostic work-up for
this unusual case and provide a comprehensive review of
the literature.
Case Presentation
Clinical Presentation
A progressive splenomegaly was observed in an other-
wise healthy 8 months-old Turkish infant during a
pediatric routine examination. The boy’s parents are
non-consanguineous and healthy, as is his 6-year old
brother. The patient’s perinatal and neonatal history was
unremarkable. An acute infection was initially suspected
due to elevated EBV and CMV antibody titers, but a
worsening clinical condition with progressive pancytope-
nia and fever prompted re-evaluation at the age of 13
months. An open liver biopsy, standard bone marrow
smear and trephine biopsy demonstrated no features of
a metabolic disorder, hematological or immunological
disease, infection, hepatic disorder (except for a mild
secondary hepatitis) or malignancy.
Over the following 5 months, the boy was not thriving
and progression of splenomegaly was obvious by palpa-
tion and increasing abdominal girth. Abdominal ultra-
sound confirmed these findings: the liver size was 13.7
cm and the spleen measured 19.1 cm without any find-
ings of abnormal vessel variations and patent hepatic
veins. The portal vein was relatively prominent with a
width of 1 cm, which in combination with markedly
increased blood flow indicates a hyperdynamic situation
(Figure 1C). We concluded that these signs were consis-
tent with increased portal pressure. Gastroscopy con-
firmed congestive gastropathy grade I. The combination
of findings led to the diagnosis of idiopathic portal
hypertension. We decided against measuring of portal
wedge pressure or partial splenic embolization due to
the significant procedure associated risks in this criti-
cally ill child. Magnetic resonance imaging of the abdo-
men showed a dramatic enlargement of the spleen with
compression of the neighboring organs (Figure 1A, B).
On scintigraphic imaging with In-111-oxinate tagged
platelets, liver and spleen exhibited significant pooling
indicating severe sequestration in these organs. The boy
received prophylactic immunization for suspected sple-
nic dysfunction.
During the next week the child’s clinical condition
deteriorated further. He developed fever (despite anti-
biotic therapy) with no signs for inflammation, severe
pancytopenia without adequate response to periodic
transfusions (platelets, erythrocytes), hemorrhagic dia-
thesis (prolonged bleeding time) and symptoms due to
compression of the bordering organs (dyspnea, refusal
to take food, and urinary retention). Due to his life-
threatening condition splenectomy was performed,
which passed without any complications. During the
surgical procedure a second liver biopsy was taken, the
spleen was explanted, and small accessory spleen was
left in situ ( F i g u r e1 D ) .T h ep o s t o p e r a t i v ec o u r s ew a s
uneventful and the boy’s condition improved rapidly. He
was discharged with an antibiotic prophylaxis and beta-
blocker medication to decrease portal pressure. When
last seen one and a half years after surgery, he was
healthy and thriving and on abdominal ultrasound his
liver size had significantly reduced in size. Furthermore,
on repeated upper endoscopy the signs of hypertensive
gastropathy disappeared. Beta-blocker medication was
discontinued without complication.
Histopathologic examination of the spleen and liver
revealed extreme hyperplasia of the lymphatic tissue
within the white pulp of the spleen (splenadenoma),
sinusoid ectasia especially in the spleen and expansion
of the portal tracts without further hepatic pathology.
For immunohistochemistry tissue samples were frozen
in liquid nitrogen and stored at -80°C until use or fixed
in buffered 4% formaldehyde and routinely embedded in
paraffin. Immunohistochemical studies were performed
with the previously described primary antibodies recog-
nizing ET-1 (monoclonal, mouse, alpha-Diagnostics,
Germany), eNOS (polyclonal, rabbit, alpha-Diagnostics,
Germany), and anti-VCAM-1 (monoclonal, mouse, BD
PharMingen, Germany). In brief, after de-paraffinization,
endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in absolute methanol for 10 min at
room temperature. After incubation with the primary
antibody for 12 hours at room temperature, sections
were exposed to the secondary biotin-conjugated goat
anti-rabbit or goat anti-mouse IgG. This was followed
by amplification using system SAB (LSAB kits, Dako,
Glostrup, Denmark) with 3,3’-diaminobenzidine hydro-
chloride. Sections were counterstained with Ehrlich
hematoxylin. Immunohistochemical staining for
endothelial nitric oxide synthetase (eNOS) and vascular
endothelial adhesion molecule-1 (VCAM-1) showed
extensive expression in the spleen but not the liver,
while endothelin-1 (ET-1) staining was weak (Figure 2).
In contrast, there was no detectable eNOS, VCAM-1,
and ET-1 expression in the spleen of a patient with liver
cirrhosis (chronic infection with hepatitis C virus) and
in a healthy control (traumatic splenic rupture). Age,
gender, splenic weight and size are summarized in
Table 1.
Serum levels of VCAM-1 and ET-1 were measured
using ELISA kits according to the manufacturer’s
instructions (VCAM-1, Human VCAM-1 ELISA KIT,
Chemicon International, Germany; ET-1, QuantiGlo,
Human Endothelin-1 Immunoassay, R&D Systems, Min-
neapolis, MN, USA). VCAM-1 concentration was
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mal range 675 - 1,690 ng/ml), while ET-1 was normal.
One year after surgery, VCAM-1 levels in serum
decreased to near normal. Due to the excellent clinical
course of the disease, no further measurements were
performed.
Splenectomy in IPH – Review of the Literature
While some reports of IPH in childhood exist, those
published so far were of patients with a much milder
disease course [6]. In our review of the literature (Table
2), a total number of 14 patients could be identified in
whom IPH was diagnosed and splenectomy was per-
formed [7-19]. None of these patients was younger than
20 years (median age 30 years, range 20-65) when pre-
senting with symptoms. There is a male predominance
with only one female patient out of 14. Our patient (age
at presentation 8 months) was also male. All patients
were found to have splenomegaly and pancytopenia.
Gastric or esophageal varices were present in nine
Figure 1 Massive hepatosplenomegaly before splenectomy. A) Magnetic resonance imaging (MRI) revealed enlargement of especially the
spleen on axial projection. The splenic enlargement resulted in a compression of the bladder (H = Head, F = Foot, R = Right, L = Left). B) On
sagittal MRI projection, compression of the left kidney was seen. The compression of other intraabdominal organs impeded alimentation
(H = Head, F = Foot, A = Anterior, P = Posterior). C) On Doppler sonography, the portal vein was relatively prominent with a width of 1 cm. Portal
vein blood flow was markedly increased. D) During surgery, the extent of splenomegaly was documented. The organ had a weight of 1.2 kg.
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pathy for one year. Abnormal liver function tests were
reported in four patients. Liver transplantation was per-
formed in one patient at the same time as splenectomy.
Histopathological features of IPH were seen in all
patients, whereas portal fibrosis was explicitly reported
in nine patients, vascular changes in four patients and
signs of (reactive) hepatitis with inflammatory cell infil-
tration in five patients.
Accompanying disease was described in 9 patients
(Table 2). An accompanying autoimmune disease (e. g.
systemic lupus erythematosus, rheumatoid arthritis) is
not uncommon in IPH patients [10,12]. Babbs et al.
report a patient with IPH who developed IgA nephropa-
thy and a nephrotic syndrome [17]. Splenectomy
resulted in remission of the nephrotic syndrome. The
cases presented by Noël et al. and Yoshimura et al. link
IPH and renal transplantation; however, not on the
basis of preexisting (autoimmune) renal disease [13,15].
The IPH case presented by Tsujimura et al. was asso-
ciated with prominent polyclonal hyperimmunoglobuli-
nemia and plasmacytosis in the bone marrow and the
spleen, persisting even after splenectomy, and suggests
an underlying chronic inflammatory state such as a con-
nective tissue disease of the liver [16]. Association of
various other diseases such as celiac disease [20], mixed
connective tissue disease [21-25], and thyreoiditis
Figure 2 Immunohistochemical analysis of liver and spleen at splenectomy. There is strong staining for eNOS especially in the
endothelium of the spleen of the IPH patient (A). In contrast, there is no detectable eNOS expression in the liver of the patient (not shown), in
the spleen of a patient with liver cirrhosis (B) and in a healthy control (C). There is a strong expression of VCAM-1 in the spleen of our patient
(D), whereas the expression is not restricted to endothelial cells but also found on stromal cells of myeloid origin. VCAM-1 staining is negative in
hepatic tissue of our patient (not shown) and there was also no staining in splenic tissue of a patient with liver cirrhosis (E) and in healthy
spleens obtained after trauma surgery (F). ET-1 is negative both in the spleen (G) and in the liver (not shown) of our patient, as well as in the
splenic tissue of a patient with liver cirrhosis (H) and a healthy control (I). IPH, idiopathic portal hypertension; LC, liver cirrhosis, eNOS, endothelial
nitric oxide synthase; VCAM-1, vascular endothelial adhesion molecule-1; ET-1, endothelin-1; Original magnifications ×200.
Table 1 Main Features of the Cases Studied
n Sex Age Splenic weight Splenic size
IPH 1 M 20 mo 1,160 g 24.0 × 12.0 × 8.0 cm
LC 1 M 51 yr 750 g 17.0 × 15.0 × 7.0 cm
Control 1 F 46 yr 94 g 9.3 × 6.8 × 4.0 cm
M, male; F, female; IPH, idiopathic portal hypertension; LC, liver cirrhosis.
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Page 4 of 7Table 2 Case Reports of Splenectomy In Idiopathic Portal Hypertension
Report Age
(yrs),
Sex
Dx Splenomegaly Thrombocytopenia Leucopenia Gastric
varices
Esophageal
varices
Encephalopathy Ab-normal
Liver function
tests
Liver
transplantation
Portal
fibrosis
Vascular
changes
Inflammation/
heaptitis
Follow-
up
Recovery
Upshaw
(1979) [19]
46, M AI yes yes yes no yes no no no yes no no 12 yr yes
Lindor
(1987) [18]
65, M Ly yes yes yes no yes no (yes) no no no no 14 mo yes
Petrowsky
(1997) [8]
30, M None yes yes yes no yes no yes yes yes yes no 26 mo yes
Sasajima
(2006) [10]
53, F RA yes yes no yes no no yes no no yes yes 12 mo yes
Ohta
(2001) [11]
59, M None NA NA NA NA NA yes NA no yes no no NA yes
Inagaki
(2000) [12]
38, M SLE yes yes yes no yes no yes no yes no yes 24 mo yes
Ziarkiewicz
(2004) [9]
21, M None yes yes yes no no no NA no yes yes no 6 mo yes
Bernard
(1995) [14]
20, M None yes yes yes no no no NA yes yes no no 14 yr yes
Yoshimura
(1994) [15]
30, M RTx yes yes yes no yes no no no yes no yes 6 yr yes
Yoshimura
(1994) [15]
22, M RTx yes yes yes no yes no no no yes no no 26 mo yes
Tsujimura
(1987) [16]
NA PHI NA NA NA NA NA no no no no yes yes NA no
Babbs
(1991) [17]
30, M IgAN yes no no no yes no no no no no no 30 mo yes
Noël (1995)
[13]
36, M RTx yes yes yes no yes no no no yes no no 12 mo yes
Treška
(2005) [7]
20, M None yes yes yes no no no no no no no yes 10 mo yes
Our Case 0.7, M None yes yes yes no no no no no no no no 18 mo yes
M, Male; F, Female; Dx, Accompanying Disease; AI, Arsenic Ingestion; Ly, Lymphoma; RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; RTx, Renal Transplantation; PHI, Polyclonal
Hyperimmunglobulinemia; IgAN, IgA Nephropathy; Mo, Months; Yr, Years; NA, Data not available.
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7[26-28] in IPH suggests that immunological disturbances
are shared with autoimmune diseases [29], though exact
mechanisms remain unclear.
The Role of the Spleen in IPH Pathogenesis
In clearer cases of IPH, splenectomy turned out to be
curative (median follow up 25 months, range 6-168
months, Table 2). The spleen seems to play a major role
in the pathogenesis of IPH as disease remission can be
observed after splenectomy in adults. It has been
described that splenectomy or even splenic transposition
may be an effective treatment of portal hypertension
alone, and the reduction in the degree of flow thru the
spleen into the portal circulation is expected to enhance
liver function and reduce portal pressures post-splenect-
omy independent of any causality of the spleen and
IPH. However, it is conceivable that the primary cause
of IPH is not related to hepatic abnormalities but rather
to abnormal splenic perfusion. Treska et al. described a
young adult male with IPH and massive splenomegaly
who was cured by splenectomy. The authors suggested,
based upon immunohistochemical results, that the
expression of VCAM-1 and ET-1 may be involved in
splenic and portal hyperperfusion [7]. They found over-
expression in IPH compared to healthy spleens. These
molecules have been suggested to influence the develop-
ment of IPH by causing hypercirculation and thereby
hypertension in the portal venous system (ET-1) or by
enhanced adhesion and migration of lymphocytes into
the wall of the portal tracts followed by fibrosis
(VCAM-1). Although the stimulus leading to augmented
production of ET-1 and VCAM-1 in the enlarged spleen
remains unknown, the circulating soluble isoforms of
these factors may be elevated in the serum of IPH
patients [7]. While VCAM-1 was also markedly elevated
in our patient, we were unable to detect ET-1, either in
serum or by immunohistochemistry. Sato et al. reported
that sinus lining cells of IPH spleens showed diffuse and
strong expression of inducible and endothelial nitric
oxide synthetase (iNOS and eNOS). In contrast, ET-1
was detectable in only a few mononuclear leukocytes in
the red pulp of IPH spleens [30]. These results suggest
that NO liberated in spleen in the presence of low ET-1,
is responsible for the dilatation of splenic sinuses, lead-
ing to splenomegaly and thereby contributing to portal
hypertension in IPH [9]. This is intriguing, since our
case represents the first case in which pathology under-
lying IPH was studied at such young age, making sec-
ondary phenomena less likely than in older patients
with long-standing portal hypertension.
On this basis, VCAM-1 overexpression would not be a
prime mechanism propagating portal hypertension but
rather a secondary event that may be related to chronic
vascular stress, inflammation, and phagocyte migration
leading to nuclear factor kappaB (NF-kB) activation
[31-33]. VCAM-1 expression may be induced in prolif-
erating cells of myeloid origin in the spleen, which can
either be a sign of extramedullary hematopoiesis or pha-
gocytic activation [32]. The immunohistochemical stain-
ing in our case revealed that VCAM-1 was expressed
not only in the endothelium but also in stromal cells.
Instead, a marked expression of eNOS was found in
splenic cells but not in the hepatic endothelium of our
patient. However, the soluble form of VCAM-1 can be
used for monitoring disease progression of IPH or the
success of partial splenic embolization [34]. While an
increase of adhesion molecules is a common phenom-
enon in cases of endothelial activation, the underlying
pathophysiology of IPH seems to be different from
arterial pulmonary hypertension of portopulmonary
hypertension, in which and increased ET-1 expression
and reduced NO lead to vasoconstriction [35,36].
Conclusions
We report the first case of uncontrolled splenic hyper-
perfusion and enlargement with subsequent hypersplen-
ism leading to life-threatening complications of IPH in
infancy and show that disease remission after splenect-
omy in early childhood points to the spleen as the main
organ underlying pathogenesis and progression of IPH.
The success of surgical interventions targeting hypers-
plenism suggests that the primary defect in the regula-
tion of splenic blood flow seems to be crucial for the
development of IPH. This view of the pathophysiology
is supported by the fact that i) liver function abnormal-
ities do not occur in IPH, ii) abnormal eNOS and
VCAM-1 expression was only seen in splenic but not
hepatic tissue, iii) the signs of portal hypertension
resolved in our patient after splenectomy, and iv) both
the adult patients reported before and our young patient
have not developed recurrent signs of portal hyperten-
sion, liver pathologies or complications after splenect-
omy. Thus, beside other treatment options (e. g. splenic
embolization, percutaneous transhepatic obliteration or
transjugular intraheptic portosystemic shunt procedure)
total (or possible partial) splenectomy needs to be con-
sidered as a prime therapeutic option for IPH.
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